Growth Metrics

Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to 207.05%.

  • Ginkgo Bioworks Holdings' EBITDA Margin fell 1459400.0% to 207.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 187.04%, marking a year-over-year increase of 1102800.0%. This contributed to the annual value of 242.39% for FY2024, which is 1110600.0% up from last year.
  • Per Ginkgo Bioworks Holdings' latest filing, its EBITDA Margin stood at 207.05% for Q3 2025, which was down 1459400.0% from 116.52% recorded in Q2 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' EBITDA Margin registered a high of 34.37% during Q3 2021, and its lowest value of 1134.55% during Q4 2021.
  • In the last 5 years, Ginkgo Bioworks Holdings' EBITDA Margin had a median value of 249.97% in 2024 and averaged 354.45%.
  • Examining YoY changes over the last 5 years, Ginkgo Bioworks Holdings' EBITDA Margin showed a top increase of 9638200bps in 2022 and a maximum decrease of -9785300bps in 2022.
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBITDA Margin (Quarter) stood at 1134.55% in 2021, then soared by 85bps to 170.73% in 2022, then plummeted by -249bps to 596.49% in 2023, then skyrocketed by 58bps to 249.97% in 2024, then grew by 17bps to 207.05% in 2025.
  • Its last three reported values are 207.05% in Q3 2025, 116.52% for Q2 2025, and 186.27% during Q1 2025.